Nuvectra Corporation (NVTR) Expected to Announce Earnings of -$1.15 Per Share

Wall Street brokerages expect Nuvectra Corporation (NASDAQ:NVTR) to announce earnings per share of ($1.15) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Nuvectra’s earnings. Nuvectra posted earnings of ($1.27) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 9.4%. The firm is scheduled to issue its next earnings report on Tuesday, March 6th.

On average, analysts expect that Nuvectra will report full-year earnings of ($4.58) per share for the current fiscal year. For the next financial year, analysts anticipate that the business will post earnings of ($3.73) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Nuvectra.

Nuvectra (NASDAQ:NVTR) last released its earnings results on Wednesday, November 1st. The company reported ($1.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.16) by $0.07. Nuvectra had a negative net margin of 204.19% and a negative return on equity of 68.63%. The business had revenue of $7.60 million during the quarter, compared to analyst estimates of $8.08 million. During the same quarter in the prior year, the firm earned ($0.92) earnings per share. The company’s revenue for the quarter was up 100.0% compared to the same quarter last year.

NVTR has been the subject of a number of analyst reports. ValuEngine lowered shares of Nuvectra from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Piper Jaffray Companies reissued a “hold” rating and issued a $12.00 price objective on shares of Nuvectra in a report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. Nuvectra currently has a consensus rating of “Hold” and an average target price of $12.00.

Shares of Nuvectra (NASDAQ NVTR) opened at $7.72 on Wednesday. The company has a current ratio of 2.90, a quick ratio of 2.72 and a debt-to-equity ratio of 0.37. Nuvectra has a 1-year low of $4.90 and a 1-year high of $15.00. The stock has a market cap of $83.36, a price-to-earnings ratio of -1.64 and a beta of -0.91.

A number of hedge funds have recently made changes to their positions in the business. Gamco Investors INC. ET AL boosted its stake in Nuvectra by 4.2% during the second quarter. Gamco Investors INC. ET AL now owns 35,194 shares of the company’s stock worth $467,000 after buying an additional 1,434 shares during the period. Wells Fargo & Company MN boosted its stake in Nuvectra by 1.3% during the second quarter. Wells Fargo & Company MN now owns 114,492 shares of the company’s stock worth $1,520,000 after buying an additional 1,495 shares during the period. Stifel Financial Corp boosted its stake in Nuvectra by 6.2% during the second quarter. Stifel Financial Corp now owns 34,227 shares of the company’s stock worth $444,000 after buying an additional 1,999 shares during the period. Northern Trust Corp boosted its stake in Nuvectra by 1.7% during the second quarter. Northern Trust Corp now owns 169,659 shares of the company’s stock worth $2,253,000 after buying an additional 2,811 shares during the period. Finally, FNY Partners Fund LP boosted its stake in Nuvectra by 449.6% during the third quarter. FNY Partners Fund LP now owns 13,740 shares of the company’s stock worth $182,000 after buying an additional 11,240 shares during the period. 58.89% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Nuvectra Corporation (NVTR) Expected to Announce Earnings of -$1.15 Per Share” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at

About Nuvectra

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.

Get a free copy of the Zacks research report on Nuvectra (NVTR)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Nuvectra (NASDAQ:NVTR)

What are top analysts saying about Nuvectra? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nuvectra and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit